Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia
NCT ID: NCT06379282
Last Updated: 2024-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
132 participants
INTERVENTIONAL
2022-10-14
2026-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
NCT02194387
HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia
NCT05879133
Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia
NCT00499759
Exercise and Quality of Life in Leukemia Patients
NCT02246907
Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
NCT00554489
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HIT Group
Exercise Only
* 3 sessions per week
* Aerobic + Resistance Exercises
HIT
Exercise training only
EXE+ Group
Exercise + Nutritional Guidance
* 3 sessions per week
* Aerobic + Resistance Exercises
* Dietary assessment at baseline and during with guidance on eating a healthy diet provided
EXE+ Nutritional Guidance
Exercise Training + Nutritional Guidance
Control Group
Control group will receive no exercise or nutritional guidance
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HIT
Exercise training only
EXE+ Nutritional Guidance
Exercise Training + Nutritional Guidance
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female ≥ 18 years of age
* Able to walk on a treadmill or cycle on an ergometer
* Pass the Physical Activity Readiness Questionnaires (PAR-Q and PAR-Q+)
Exclusion Criteria
* Secondary malignancy within 3 years of study enrollment requiring intervention except for adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localised prostate cancer and PSA stable.
* Absolute contraindications to exercise: Recent (\<6 months) acute cardiac event unstable angina, uncontrolled dysrhythmias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspected or known dissecting aneurism and acute systemic infection.
* Significant orthopaedic limitations, musculoskeletal disease and/or injury. Due to the nature of the study, persons with known joint, muscle or other orthopaedic limitations that restrict physical activity may be excluded.
* Type I diabetes mellitus or uncontrolled Type II diabetes mellitus, or chronic obstructive pulmonary disease
* Uncontrolled blood pressure (≥180/90) at rest
* Known concurrent HIV, Hepatitis B or Hepatitis C
* Unable to comply with other study requirements
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American Society of Hematology
OTHER
University of Surrey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Bartlett
Senior Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Bartlett, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Surrey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Surrey
Guildford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FHMS 21-22 263 EGA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.